26 related articles for article (PubMed ID: 24646918)
1. An Improved
Mangir N; Raza A; Haycock JW; Chapple C; Macneil S
In Vivo; 2018; 32(3):461-472. PubMed ID: 29695547
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Takaha N; Okihara K; Kamoi K; Hongo F; Iwata T; Yano K; Ueda T; Takeuchi I; Yamada T; Kawauchi A; Miki T
Urol Int; 2011; 87(3):263-9. PubMed ID: 21876321
[TBL] [Abstract][Full Text] [Related]
4. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer.
Mangir N; Türkeri L
Actas Urol Esp; 2014 Oct; 38(8):515-22. PubMed ID: 24646918
[TBL] [Abstract][Full Text] [Related]
7. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
8. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
9. Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?
Climent MÁ; Torregrosa MD; Vázquez S; Gironés R; Arranz JA
Cancer Treat Rev; 2017 Apr; 55():173-180. PubMed ID: 28411479
[TBL] [Abstract][Full Text] [Related]
10. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Gyawali B; Koomulli-Parambil S; Iddawela M
Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
[TBL] [Abstract][Full Text] [Related]
11. [Updated treatment of castration-resistant prostate cancer].
Xu S; Zhang ZY
Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]